Bioscience

Breast cancer drug Abraxane promising for malignant melanoma treatment

July 20, 2009

By Flinn Foundation

An approved breast-cancer drug nab-paclitaxel, trade named Abraxane, has been found promising in clinical trial for the treatment of metastatic malignant melanoma, revealed by researchers.

 

Researchers at the Arizona Cancer Center has used this drug for last 7 years, and resulted in the opening of a Phase 3 clinical trial.

 

For more information: Breast cancer drug Abraxane promising for malignant melanoma treatment